Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
P/E ratio for Avacta Group Plc (AVCT.L)
P/E ratio as of 2023: -12.73
According to Avacta Group Plc's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -12.73. At the end of 2022 the company had a P/E ratio of -7.44.
P/E ratio history for Avacta Group Plc from 2000 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -12.73 |
| 2022 | -7.44 |
| 2021 | -11.98 |
| 2020 | -13.61 |
| 2019 | -1.88 |
| 2018 | -1.83 |
| 2017 | -8.70 |
| 2016 | -12.60 |
| 2015 | -6.99 |
| 2014 | -29.43 |
| 2013 | -17.53 |
| 2012 | -17.18 |
| 2011 | -26.46 |
| 2010 | -5.20 |
| 2009 | -5.30 |
| 2008 | -20.46 |
| 2007 | -31.95 |
| 2005 | -242.67 |
| 2004 | -23.54 |
| 2003 | -87.13 |
| 2002 | -233.93 |
| 2001 | -156.42 |
| 2000 | -173.11 |